Pirfenidone

Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.

Amy Hajari Case, MD, FCCP, has been named chief medical officer of the Pulmonary Fibrosis Foundation, according to a press release.

Among patients with COVID-19 and acute respiratory failure, survival at 1 year was more likely if they received nintedanib or pirfenidone antifibrotics, according to results published in BMC Pulmonary Medicine.

HONOLULU — Treatment with nintedanib plus pirfenidone resulted in a similar frequency of adverse events as monotherapy among patients with idiopathic pulmonary fibrosis, according to a systemic review presented at the CHEST Annual Meeting.

The Healio Editors compiled the most-read news in pulmonology posted in September.

In the phase 2 TRAIL1 trial, treatment with pirfenidone slowed the rate of lung function decline in patients with rheumatoid arthritis-associated interstitial lung disease and demonstrated a similar safety profile to that observed in other trials of the drug.

Use of electronic monitoring systems helped identify prevalent medication nonadherence in patients with idiopathic pulmonary fibrosis taking pirfenidone, according to data published in ERJ Open Research.

Concomitant medication burden is associated with antifibrotic medication intolerance among patients with idiopathic pulmonary fibrosis, according to research published in Annals of the American Thoracic Society.

SAN FRANCISCO — A session at the American Thoracic Society International Conference highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults.

In a new study, concomitant medication burden was associated with antifibrotic medication intolerance in patients with idiopathic pulmonary fibrosis.